3[3]Gupta S,Clarkson MR,Duggan J,et al.Connective tissue growth factor:potential role in glmerulosclerosis and tubulointerstitial fibrosis[J].Kidney Int,2000,58 (4):1389-1399.
4[4]Sakharova OV,Taal M W,Brenner BM.Pathogenesis of diabetic nephropathy:focus on transforming growth factor beta and connective tissue growth factor[J].Curr Opin Nephrol Hypertens,2001,10(6):727-738.
5[5]Leask A,Sa S,Holmes A,et al.The control of ccn2 (CTGF) gene expression in normal and scleroderma fribroblasts[J].Mol Pathol,2001,54 (3):180-183.
6[6]Dammeier J,Beer H,Brauchle M,et al.Dexamethasone is a novel potent inducer of connective tissue growth factor expression[J].J Biol Chem,1998,273 (29):18185-18190.
7[7]Murphy M,Godson C,Cannon S,et al.Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells[J].J Biol Chem,1999,274(9):5830-5834.
8[8]Wang S,Denichilo M,Brubaker C,et al.Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy[J].Kidney Int,2001,60(1):96-105.
10[10]Twigg SM,Joly AH,Chen MM,et al.Connective tissue growth factor IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end products in human dermal fibroblasts[J].Endocrinology,2002,143 (4):1260.
二级参考文献21
1Zheng F, Fomoni A, Eliot SJ, et al. Upregulation of type I collagenby TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol, 2002,282 : F639-648.
2Guan Y, Zhang Y, Schneider A, et al. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature. Am J Physiol Renal Physiol, 2001,281 : F1036-1046.
3Shappell SB, Gurpinar T, Lechago J, et al. Chronic obstructive uropathy in severe combined immunodeficient (SCID) mice:lymphocyte infiltration is not required for progressive tubulointerstitial injury. J Am Soc Nephrol, 1998,9 : 1008-1017.
4Hogan BLM. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev, 1996,10 : 1580-1594.
5Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med ,2001,52:239-257.
6Berger J ,Moller DE. The mechanisms of action of PPARs. Annu Rev Med ,2002,53:409-435.
7Kon K, Ikejima K, Hirose M, et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biohys Res Commun ,2002,291:55-61.
8Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology ,2002,122 : 1924-1940.
9Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferation-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002,106:3126-3132.
10Ma LJ, Marcantoni C, Linton MF, et al. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int, 2001,59 : 1899-1910.
